Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen
Unknown status
Ferring Pharmaceuticals
Phase 2
2009-06-01
The objective of the study is to confirm that the efficacy of vaginal progesterone is at
least as good as oral progesterone in order to protect the endometrium of uncontrolled
proliferation and prevent endometrial cancer.
Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen
Unknown status
Rabin Medical Center
Phase 2
2009-06-01
The objective of the study is to confirm that the efficacy of vaginal progesterone is at
least as good as oral progesterone in order to protect the endometrium of uncontrolled
proliferation and prevent endometrial cancer.
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions
Completed
Teva Pharmaceuticals USA
Phase 1
2007-02-01
The objective of this study was to determine and compare the rate and extent of absorption of
norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone
Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg
norethindrone acetate) Tablets under fasting conditions.
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
Completed
Teva Pharmaceuticals USA
Phase 1
2007-01-01
The objective of this study was to determine and compare the rate and extent of absorption of
norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone
Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg
norethindrone acetate) Tablets under fed conditions.
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Completed
AbbVie
Phase 2
2013-04-08
This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety
and efficacy of elagolix alone and in combination with add-back therapy versus placebo on
heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
